Moderna

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2010-01-01

Employees: 5.6K

Market Cap: $30.3B

Website: http://www.modernatx.com

Introduction: Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Clinical Trials

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Phase 1

Recruiting

Conditions: Methylmalonic Acidemia

Interventions: Biological: mRNA-3705

First Posted Date: 2021-05-24

Last Posted Date: 2025-03-25

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 63

Registration Number: NCT04899310

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 14 locations

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Phase 3

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273

First Posted Date: 2021-04-26

Last Posted Date: 2024-06-18

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 234

Registration Number: NCT04860297

Locations: 🇺🇸
Aventiv Research Inc, Mesa, Arizona, United States
🇺🇸
California Institute of Renal Research, San Diego, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 12 locations

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Phase 1

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1283
Biological: mRNA-1273
Biological: Placebo

First Posted Date: 2021-03-24

Last Posted Date: 2023-08-01

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 104

Registration Number: NCT04813796

Locations: 🇺🇸
Synexus Clinical Research US Phoenix Southeast, Inc., Chandler, Arizona, United States
🇺🇸
Optimal Research San Diego, LLC, San Diego, California, United States
🇺🇸
Optimal Research Melbourne, LLC, Melbourne, Florida, United States

and more 2 locations

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273
Biological: Placebo
Biological: mRNA-1273.214

First Posted Date: 2021-03-15

Last Posted Date: 2025-06-13

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 11942

Registration Number: NCT04796896

Locations: 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
MedPharmics, LLC, Albuquerque, New Mexico, United States
🇺🇸
Emmaus Research Center Inc, Anaheim, California, United States

and more 87 locations

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273
Biological: Placebo
Biological: mRNA-1273.222

First Posted Date: 2020-12-02

Last Posted Date: 2024-10-22

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 4331

Registration Number: NCT04649151

Locations: 🇺🇸
Velocity Clinical Research - Banning, Banning, California, United States
🇺🇸
Paradigm Clinical Research, La Mesa, California, United States
🇺🇸
Altus Research - Hunt - PPDS, Lake Worth, Florida, United States

and more 49 locations

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Phase 1

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: mRNA-1345
Drug: Placebo

First Posted Date: 2020-08-27

Last Posted Date: 2024-08-07

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 651

Registration Number: NCT04528719

Locations: 🇺🇸
Paradigm Clinical Research Institute Inc - ClinEdge - PPDS, La Mesa, California, United States
🇺🇸
Mills Clinical Research, West Hollywood, California, United States
🇺🇸
Accel Research Site - Angel Kids Pediatrics - ERN - PPDS, DeLand, Florida, United States

and more 28 locations

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Phase 3

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273
Biological: Placebo

First Posted Date: 2020-07-14

Last Posted Date: 2024-03-21

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 30415

Registration Number: NCT04470427

Locations: 🇺🇸
Ascension St. Vincent Birmingham, Birmingham, Alabama, United States
🇺🇸
Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States
🇺🇸
Hope Research Institute, Phoenix, Arizona, United States

and more 87 locations

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273.351
Biological: Placebo

First Posted Date: 2020-05-28

Last Posted Date: 2022-12-30

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 660

Registration Number: NCT04405076

Locations: 🇺🇸
Meridian Clinical Research, Dakota Dunes, South Dakota, United States
🇺🇸
Alliance for Multispecialty Research, Kansas City, Missouri, United States
🇺🇸
Trial Management Associates, Wilmington, North Carolina, United States

and more 1 locations

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Phase 2

Completed

Conditions: Cytomegalovirus Infection

Interventions: Other: Placebo
Biological: mRNA-1647

First Posted Date: 2020-01-18

Last Posted Date: 2024-01-03

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 315

Registration Number: NCT04232280

Locations: 🇺🇸
Benchmark Research, Sacramento, California, United States
🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States

and more 6 locations

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Phase 1

Recruiting

Conditions: Propionic Acidemia

Interventions: Biological: mRNA-3927

First Posted Date: 2019-11-12

Last Posted Date: 2025-03-28

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 68

Registration Number: NCT04159103

Locations: 🇯🇵
Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
🇯🇵
Tohoku University Hospital, Sendai-Shi, Miyagi, Japan
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 14 locations

AI-Powered Research

Premium Access

Moderna

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia